Last reviewed · How we verify
avoidance of GABAergic-drugs strategy
avoidance of GABAergic-drugs strategy is a Small molecule drug developed by Ente Ospedaliero Ospedali Galliera. It is currently in Phase 1 development.
At a glance
| Generic name | avoidance of GABAergic-drugs strategy |
|---|---|
| Sponsor | Ente Ospedaliero Ospedali Galliera |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- avoidance of GABAergic-drugs strategy CI brief — competitive landscape report
- avoidance of GABAergic-drugs strategy updates RSS · CI watch RSS
- Ente Ospedaliero Ospedali Galliera portfolio CI
Frequently asked questions about avoidance of GABAergic-drugs strategy
What is avoidance of GABAergic-drugs strategy?
avoidance of GABAergic-drugs strategy is a Small molecule drug developed by Ente Ospedaliero Ospedali Galliera.
Who makes avoidance of GABAergic-drugs strategy?
avoidance of GABAergic-drugs strategy is developed by Ente Ospedaliero Ospedali Galliera (see full Ente Ospedaliero Ospedali Galliera pipeline at /company/ente-ospedaliero-ospedali-galliera).
What development phase is avoidance of GABAergic-drugs strategy in?
avoidance of GABAergic-drugs strategy is in Phase 1.